Belgium’s Tigenix says heart attack stem cell trial successful – Reuters
The Times |
Belgium's Tigenix says heart attack stem cell trial successful
Reuters The group said patients treated in its PhaseI/II trial of donor-derived expanded cardiac stem cells (AlloCSC) showed no side-effects and all of them continued to live after 30 days, six months and a year. Tigenix added that in one subgroup of trial … TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction |
